Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (NASDAQ: ARTL) has been accepted into the Alderley Park Oncology Development Program in the UK, which aims to support innovative oncology projects. This program, funded by Innovate UK and Cancer Research UK, could provide additional funding to Artelo's FABP5 inhibitor program, which has previously received nearly $8 million from the U.S. government. The program focuses on developing a pathway to validate FABP5 as a biomarker across multiple tumor types, suggesting broader applicability of ART26.12 in cancer therapy.
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that CEO Gregory Gorgas will present at the Q1 Virtual Investor Summit from March 23-25, 2021. The presentation is scheduled for March 23rd at 1:00 PM ET. This summit connects smallcap and microcap companies with qualified investors, featuring over 100 companies and 300 investors. Artelo focuses on developing therapeutics targeting lipid-signaling pathways, aiming to address significant health concerns such as cancer and pain. For more details, visit www.artelobio.com.
Artelo Biosciences (NASDAQ: ARTL) announced the appointment of Tamara A. Seymour, CPA, to its board of directors. Ms. Seymour brings over 30 years of experience in corporate finance within the biotech sector, having successfully raised over $250 million in funding. Her background includes serving as CFO for various public and venture-backed companies, along with expertise in clinical development and commercialization. The board believes her insights will be crucial for Artelo's growth as it seeks to advance its therapeutic programs targeting lipid-signaling pathways.
Artelo Biosciences (NASDAQ: ARTL) will present at the H.C. Wainwright Life Sciences Conference, scheduled for March 9-10, 2021. Gregory Gorgas, CEO, will provide insights on the company's development of therapeutics targeting the endocannabinoid system. The presentation will be available on-demand from March 9 at 7:00 AM Eastern Time on the conference platform. Additionally, Artelo's management will hold one-on-one meetings with qualified investors during the event, highlighting its focus on addressing unmet needs in various diseases.
Artelo Biosciences (NASDAQ: ARTL) announced promising findings from research highlighting the co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cancer cell models. Conducted by experts from the University of Nottingham, the study suggests enhanced anti-cancer effects through synergistic interactions between the two compounds, although a slight reduction in CBD's anti-migration effect was noted. Artelo aims for further in vivo research and has secured a composition of matter patent, opening opportunities for clinical approval and market exclusivity for its CBD:TMP cocrystal program.
Artelo Biosciences (NASDAQ: ARTL) has appointed Andrew Yates, Ph.D., as Senior VP and Chief Scientific Officer, effective immediately. Yates brings extensive experience from AstraZeneca, where he played key roles in drug development and strategy. He will lead the R&D efforts and engage with the Scientific Advisory Board, enhancing Artelo's clinical development initiatives, particularly for ART27.13, aimed at addressing cancer-related anorexia. His appointment is expected to strengthen the company's capabilities in developing therapies for various conditions, including PTSD and pain.
Artelo Biosciences (NASDAQ: ARTL) announced the exercise of warrants from its October 2020 financing, resulting in net proceeds of approximately $3 million. This strengthens the company's balance sheet, leading to a pro-forma cash balance of $10.4 million as of November 30, 2020. The capital raised will be utilized to advance the company’s product development aimed at addressing unmet needs in various diseases, including cancer and pain.
Artelo Biosciences (NASDAQ: ARTL) will present at the LSX World Congress virtually from February 1-5, 2021. The presentation will be available on-demand to registered attendees until February 28, 2021. This event brings together key executives in healthcare and life sciences, providing a platform for investment and strategic discussions. Artelo focuses on therapeutics targeting the endocannabinoid system, addressing conditions like cancer and pain. More details can be found at their website.
Artelo Biosciences (ARTL) announced the receipt of Clinical Trials Authorization for its Cancer Appetite Recovery Study (CAReS) of ART27.13 in the UK. This Phase I/II trial targets cancer patients suffering from anorexia, addressing a significant unmet medical need. The company also secured a Mitacs Accelerate grant to further develop its ART26.12 program, exploring its potential in treating anxiety disorders. Financially, ARTL reported a net loss of $1.43 million for Q1 FY2021, with operating expenses slightly rising to $1.44 million.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. EDT and accessible for 90 days. Artelo is focused on developing therapeutics that modulate the endocannabinoid system to address unmet medical needs in conditions such as cancer, PTSD, and pain. The company is based in San Diego and is advancing a portfolio of product candidates aimed at various diseases.